Complete Cerebrospinal Fluid Response to T-DM1 in HER2 Positive Metastatic Breast Cancer: A Case Report
Leptomeningeal carcinomatosis is a rare but serious consequence of pre-existing tumors, such as breast, lung, and gastrointestinal carcinomas. Further, leptomeningeal carcinomatosis is more frequently diagnosed with breast cancers, if only because breast cancers are diagnosed far more often than any...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/13/3/756 |
| _version_ | 1797610558954930176 |
|---|---|
| author | Francesca Zacchi Elena Giontella Alessia Nottegar Elena Fiorio |
| author_facet | Francesca Zacchi Elena Giontella Alessia Nottegar Elena Fiorio |
| author_sort | Francesca Zacchi |
| collection | DOAJ |
| description | Leptomeningeal carcinomatosis is a rare but serious consequence of pre-existing tumors, such as breast, lung, and gastrointestinal carcinomas. Further, leptomeningeal carcinomatosis is more frequently diagnosed with breast cancers, if only because breast cancers are diagnosed far more often than any other carcinomas. In this paper, we present the case of a leptomeningeal carcinomatosis patient who experienced complete remission following therapy targeted at the Her-2 (human epidermal growth factor receptor 2-positive) receptor. This patient’s diagnosis was complicated by the fact that brain and column MRI imaging were clear, but analysis of the cerebrospinal fluid led to the conclusion of leptomeningeal carcinomatosis. The tests were requested because the patient, under chemotherapy for advanced breast cancer at the time, reported some neurological symptoms. Following the diagnosis of leptomeningeal carcinomatosis and subsequent T-DM1 Her-2 receptor therapy, the patient showed a complete response to leptomeningeal carcinomatosis within 30 days and survived for another 16 months. This case offers compelling evidence that the effect TDM1 Her-2 receptor therapy has on a patient’s remission and long-term survivability is considerably better than other therapies for similar pre-existing conditions diagnosed with leptomeningeal carcinomatosis. Further prospective studies should confirm these findings. |
| first_indexed | 2024-03-11T06:16:52Z |
| format | Article |
| id | doaj.art-1076f312cc2847eeba54ec85855f0889 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-11T06:16:52Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-1076f312cc2847eeba54ec85855f08892023-11-17T12:11:56ZengMDPI AGLife2075-17292023-03-0113375610.3390/life13030756Complete Cerebrospinal Fluid Response to T-DM1 in HER2 Positive Metastatic Breast Cancer: A Case ReportFrancesca Zacchi0Elena Giontella1Alessia Nottegar2Elena Fiorio3Section of Oncology, Department of Medicine, University and Hospital Trust of Verona, 37126 Verona, ItalySection of Oncology, Department of Medicine, University and Hospital Trust of Verona, 37126 Verona, ItalyDepartment of Pathology and Diagnostics, University and Hospital Trust of Verona, 37126 Verona, ItalySection of Oncology, Department of Medicine, University and Hospital Trust of Verona, 37126 Verona, ItalyLeptomeningeal carcinomatosis is a rare but serious consequence of pre-existing tumors, such as breast, lung, and gastrointestinal carcinomas. Further, leptomeningeal carcinomatosis is more frequently diagnosed with breast cancers, if only because breast cancers are diagnosed far more often than any other carcinomas. In this paper, we present the case of a leptomeningeal carcinomatosis patient who experienced complete remission following therapy targeted at the Her-2 (human epidermal growth factor receptor 2-positive) receptor. This patient’s diagnosis was complicated by the fact that brain and column MRI imaging were clear, but analysis of the cerebrospinal fluid led to the conclusion of leptomeningeal carcinomatosis. The tests were requested because the patient, under chemotherapy for advanced breast cancer at the time, reported some neurological symptoms. Following the diagnosis of leptomeningeal carcinomatosis and subsequent T-DM1 Her-2 receptor therapy, the patient showed a complete response to leptomeningeal carcinomatosis within 30 days and survived for another 16 months. This case offers compelling evidence that the effect TDM1 Her-2 receptor therapy has on a patient’s remission and long-term survivability is considerably better than other therapies for similar pre-existing conditions diagnosed with leptomeningeal carcinomatosis. Further prospective studies should confirm these findings.https://www.mdpi.com/2075-1729/13/3/756breast cancerleptomeningeal carcinomatosisleptomeningeal metastasisanti-HER2 therapyhuman epidermal growth factor receptor 2cerebrospinal fluid |
| spellingShingle | Francesca Zacchi Elena Giontella Alessia Nottegar Elena Fiorio Complete Cerebrospinal Fluid Response to T-DM1 in HER2 Positive Metastatic Breast Cancer: A Case Report Life breast cancer leptomeningeal carcinomatosis leptomeningeal metastasis anti-HER2 therapy human epidermal growth factor receptor 2 cerebrospinal fluid |
| title | Complete Cerebrospinal Fluid Response to T-DM1 in HER2 Positive Metastatic Breast Cancer: A Case Report |
| title_full | Complete Cerebrospinal Fluid Response to T-DM1 in HER2 Positive Metastatic Breast Cancer: A Case Report |
| title_fullStr | Complete Cerebrospinal Fluid Response to T-DM1 in HER2 Positive Metastatic Breast Cancer: A Case Report |
| title_full_unstemmed | Complete Cerebrospinal Fluid Response to T-DM1 in HER2 Positive Metastatic Breast Cancer: A Case Report |
| title_short | Complete Cerebrospinal Fluid Response to T-DM1 in HER2 Positive Metastatic Breast Cancer: A Case Report |
| title_sort | complete cerebrospinal fluid response to t dm1 in her2 positive metastatic breast cancer a case report |
| topic | breast cancer leptomeningeal carcinomatosis leptomeningeal metastasis anti-HER2 therapy human epidermal growth factor receptor 2 cerebrospinal fluid |
| url | https://www.mdpi.com/2075-1729/13/3/756 |
| work_keys_str_mv | AT francescazacchi completecerebrospinalfluidresponsetotdm1inher2positivemetastaticbreastcanceracasereport AT elenagiontella completecerebrospinalfluidresponsetotdm1inher2positivemetastaticbreastcanceracasereport AT alessianottegar completecerebrospinalfluidresponsetotdm1inher2positivemetastaticbreastcanceracasereport AT elenafiorio completecerebrospinalfluidresponsetotdm1inher2positivemetastaticbreastcanceracasereport |